AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02513940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
Study NCT02455856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.
Study NCT02455856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
Study NCT01407978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval P monovalent influenza vaccine
Description: * Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose.
Study NCT01407978 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Fluval AB
Description: * Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose.
Study NCT01407978 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Fluval AB Novo
Description: * Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose.
Study NCT04366583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: argon plasma coagulation
Description: Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
Study NCT04366583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemoclipping
Description: clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
Study NCT04116697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
Study NCT04116697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
Study NCT01433978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Study NCT01433978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avatrombopag
Study NCT01433978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Study NCT01433978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Study NCT01433978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Study NCT04169412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
Study NCT03834259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sitting position
Description: keeping the patient in a sitting position after spinal anaesthesia
Study NCT03834259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine position
Description: keeping the patient in supine position after spinal anaesthesia
Study NCT02080728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 500mg/100ml Naropeine
Study NCT02080728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride BAXTER
Study NCT02883933 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT05889000 — intervention group
Intervention type: OTHER
Intervention: questionnaire responses
Description: questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
Study NCT04171310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442168
Description: Pharmaceutical form:oral solution Route of administration: Oral
Study NCT01818310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A: Intramuscular
Description: Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes.
Study NCT01818310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B: Intraarterial
Description: Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
Study NCT01818310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group C: Intravenous
Description: Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
Study NCT01818310 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group D: Surgical endovascular treatment with maximum medicamentous treatment
Description: Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
Study NCT00965328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH 4 to 2 L/h
Description: CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
Study NCT00965328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH 2 to 4L/h
Description: CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
Study NCT00721890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double-Brewed Green Tea
Description: liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
Study NCT02266862 — intervention group
Intervention type: RADIATION
Intervention: Study group
Description: Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
Study NCT02513940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study NCT02318108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentored organizational change
Description: Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
Study NCT02513940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules
Study NCT02513940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
Study NCT02318108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education only
Description: Practices are given basic education related to population-based care and are given feedback on performance.
Study NCT01531803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kedbumin 25%
Description: Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin).
Study NCT02349230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astym treatment
Description: Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
Study NCT02349230 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Astym treatment
Description: Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
Study NCT00129714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical collar
Study NCT00129714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Study NCT05671120 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcutaneous levator recession
Description: recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
Study NCT00537823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT04080076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar 80 UNT/ML Injectable Solution
Description: ACTHar 80 Units SQ 1042 x Week
Study NCT00537823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00537823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT00537823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00537823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study NCT03043365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control fish oil
Description: 4 capsules, 3 times a day after meals
Study NCT01531803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Description: Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
Study NCT01064960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips MR-guided HIFU system
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
Study NCT03255733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Therapeutic Ultrasound Treatment
Study NCT02007863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transfusion
Description: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
Study NCT02007863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
Study NCT02007863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
Study NCT02007863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
Study NCT04640987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
Study NCT00665925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium (R935788)
Description: 100 mg tablet, orally, twice-a-day
Study NCT00665925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium (R935788)
Description: 150 mg tablet, orally, once a day
Study NCT00665925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, either once a day, or twice a day
Study NCT03591276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Drugs, Cancer
Description: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
Study NCT03987295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL001
Description: 60 mg/kg of AL001 every 4 weeks
Study NCT00393276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Combined hepatitis A and hepatitis B immunization
Study NCT00393276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decavac
Description: Diphtheria and tetanus toxoid vaccine
Study NCT01059058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MI Paste Plus
Description: A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
Study NCT01059058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PreviDent Fluoride Varnish
Description: A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
Study NCT01059058 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Home Care
Description: Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
Study NCT01059058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Home Care
Description: Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
Study NCT01628887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo Bilingual Breast Cancer Educational Intervention
Study NCT00633022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOSMAPIMOD 7.5 MG
Description: GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
Study NCT00633022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
Study NCT03546738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
Study NCT03546738 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
Study NCT03546738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham spinal cord stimulation
Description: No spinal cord stimulation is provided
Study NCT03546738 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham spinal cord stimulation
Description: No spinal cord stimulation is provided
Study NCT03546738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS implant
Description: a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead.
Study NCT03085121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal femoral resection in total knee arthroplasty
Description: EM and IM alignment systems are used to make the distal femoral cut in a random order.
Study NCT03085121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal femoral resection in total knee arthroplasty
Description: EM and IM alignment systems are used to make the distal femoral cut in a random order.
Study NCT03546738 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SCS implant
Description: a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead.
Study NCT01685255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epacadostat
Study NCT01685255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Study NCT00583999 — intervention group
Intervention type: OTHER
Intervention: no interventions, only regular blood-draw
Description: No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
Study NCT01373515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: 4 bi-weekly vaccinations
Study NCT03067987 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.
Description: This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~.
Study NCT01140672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
Study NCT01140672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
Study NCT01140672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.